Month: July 2024

Critical Metals Corp Completes Stage 1 of the Tanbreez Acquisition, One of the World’s Largest Rare Earth Deposits

Written by Customer Service on July 23, 2024. Posted in Mergers And Acquisitions.

Critical Metals Corp Board of Directors Concludes Due Diligence on Tanbreez Acquisition; Critical Metals Corp Issues 8.4 Million Ordinary Shares to Acquire 36.45% of Outstanding Shares of Tanbreez Mining Greenland A/S NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) — Critical Metals Corp (Nasdaq: CRML) (“Critical Metals Corp”), a leading mining development company focused on critical metals and minerals and producing strategic products essential to electrification and next generation technologies for Europe and its Western world partners, today announced that it has completed Stage 1 of its recently announced plan to acquire a controlling interest in the Tanbreez Greenland Rare Earth Mine (the “Tanbreez Project”) from Rimbal Pty Ltd., a company controlled by geologist Gregory Barnes (“Rimbal”). In exchange for a 36.45% interest in Tanbreez...

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Written by Customer Service on July 23, 2024. Posted in Earnings Releases And Operating Results.

BOSTON, July 23, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA on Tuesday,...

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

Written by Customer Service on July 23, 2024. Posted in Earnings Releases And Operating Results.

– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $405 – $415 million –– Abiprubart clinical development fully funded; Phase 2b clinical trial in Sjögren’s Disease enrolling patients –– Kiniksa expects to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 23, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second quarter 2024 financial results and recent portfolio execution. “Kiniksa’s work to establish ARCALYST as the...

Dime Community Bancshares, Inc. Reports Second Quarter 2024 Results With Earnings Per Share Increasing By 5% Versus the Prior Quarter

Written by Customer Service on July 23, 2024. Posted in Earnings Releases And Operating Results.

Strong Core Deposit Growth Drives 20 Basis Points of Net Interest Margin Expansion Deposit and Business Loan Growth Driven by Execution of Growth Plan;Successfully Onboarded Eight New Deposit Groups in the Second Quarter Subordinated Debt Offering Bolsters Total Capital Ratio to 14.5% HAUPPAUGE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $16.7 million for the quarter ended June 30, 2024, or $0.43 per diluted common share, compared to $15.9 million, or $0.41 per diluted common share, for the quarter ended March 31, 2024, and $25.7 million, or $0.66 per diluted common share for the quarter ended June 30, 2023. Stuart H. Lubow, President and Chief...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

Written by Customer Service on July 23, 2024. Posted in Mergers And Acquisitions.

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies. “With the completion of the divestiture, we take an important step toward achieving our goal of significantly reducing expenses...

Sandy Spring Bancorp Reports Second Quarter Earnings of $22.8 Million

Written by Customer Service on July 23, 2024. Posted in Public Companies.

OLNEY, Md., July 23, 2024 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq-SASR), the parent company of Sandy Spring Bank, reported net income of $22.8 million ($0.51 per diluted common share) for the quarter ended June 30, 2024, compared to net income of $20.4 million ($0.45 per diluted common share) for the first quarter of 2024 and $24.7 million ($0.55 per diluted common share) for the second quarter of 2023. Current quarter’s core earnings were $24.4 million ($0.54 per diluted common share), compared to $21.9 million ($0.49 per diluted common share) for the quarter ended March 31, 2024 and $27.1 million ($0.60 per diluted common share) for the quarter ended June 30, 2023. Core earnings exclude the after-tax impact of amortization of intangibles, investment securities gains or losses and other non-recurring or extraordinary...

Lassila & Tikanoja plc will publish Half-Year Report January-June on 7 August 2024

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Lassila & Tikanoja plc Investor News 23 July 2024 2.00 pm Lassila & Tikanoja plc will publish Half-Year Report January-June on 7 August 2024 Lassila & Tikanoja plc will publish Half-Year Report January-June on Wednesday 7 August 2024 at 8.00 am. After publication, the release will be available on the company’s website at www.lt.fi/en. Lassila & Tikanoja will host a webcast for analysts, investors and media on 7 August 2024 at 10.30 am EET. The presentation material will be published on the company’s website. The English language briefing will be hosted by CEO Eero Hautaniemi and CFO Joni Sorsanen. Conference call You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. https://palvelu.flik.fi/teleconference/?id=50049975 Webcast...

PyroGenesis Announces Corporate Name Change of Subsidiary Drosrite International to PyroGenesis International

Written by Customer Service on July 23, 2024. Posted in Public Companies.

MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce that its subsidiary Drosrite International (DI) will henceforth be named PyroGenesis International. The Company’s Board of Directors is currently reviewing various locations in the United States where PyroGenesis International could be located. As announced previously in a news release on July 8, 2024, the Company has purchased 100% control of DI, a US-based private company. DI had already been, on an accounting basis, a subsidiary of...

Canoo Announces Details for Q2 2024 Earnings Conference Call and Webcast

Written by Customer Service on July 23, 2024. Posted in Public Companies.

JUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced that it will report its financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, August 14, 2024 and host a conference call and webcast at 5 p.m. ET to discuss the results. The call will be hosted by Tony Aquila, Investor, Executive Chairman and Chief Executive Officer, Greg Ethridge, Chief Financial Officer and Ramesh Murthy, Senior Vice President, Finance and Chief Accounting Officer. Conference Call and Webcast DetailsA slide presentation and webcast link will be posted on the Canoo Investor Relations website at investors.canoo.com. To listen to the conference call by phone, dial 1-877-407-9169 in the U.S., or 1-201-493-6755 Internationally. The Conference...

Alector to Present Data on Pipeline Focus Areas at the Alzheimer’s Association International Conference® (AAIC®) 2024

Written by Customer Service on July 23, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer’s Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 Presentations TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95594)Presenting Author: Arthur J. Mayorga, Ph.D., Vice President, Clinical...

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals